EP0859636A4 - Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine - Google Patents

Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine

Info

Publication number
EP0859636A4
EP0859636A4 EP96934189A EP96934189A EP0859636A4 EP 0859636 A4 EP0859636 A4 EP 0859636A4 EP 96934189 A EP96934189 A EP 96934189A EP 96934189 A EP96934189 A EP 96934189A EP 0859636 A4 EP0859636 A4 EP 0859636A4
Authority
EP
European Patent Office
Prior art keywords
dna
hyaluronic acid
gene therapy
treat abnormal
retinal vascularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96934189A
Other languages
German (de)
English (en)
Other versions
EP0859636A1 (fr
Inventor
Piroska Elizabeth Rakoczy
Ian Jeffrey Constable
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Hyal Pharmaceutical Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN6161A external-priority patent/AUPN616195A0/en
Priority claimed from AUPN9047A external-priority patent/AUPN904796A0/en
Application filed by Hyal Pharmaceutical Australia Ltd filed Critical Hyal Pharmaceutical Australia Ltd
Publication of EP0859636A1 publication Critical patent/EP0859636A1/fr
Publication of EP0859636A4 publication Critical patent/EP0859636A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22027—Cathepsin S (3.4.22.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention porte sur des méthodes de thérapie génique ainsi que sur les compositions correspondantes, y compris une thérapie anti-sens. Dans un mode de réalisation, les compositions contiennent de l'acide hyaluronique afin de stimuler l'absorption d'acide nucléique par les cellules cibles. A titre d'exemple, cette invention trouve une application dans le traitement de maladies rétiniennes causées par une néoformation de vaisseaux sanguins.
EP96934189A 1995-10-23 1996-10-22 Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine Withdrawn EP0859636A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPN6161A AUPN616195A0 (en) 1995-10-23 1995-10-23 Method and composition for treatment of ocular diseases
AUPN0616/19 1995-10-23
AUPN9047A AUPN904796A0 (en) 1996-04-01 1996-04-01 Method and composition for treatment of ocular diseases
AUPN0904/79 1996-04-01
PCT/AU1996/000664 WO1997015330A1 (fr) 1995-10-23 1996-10-22 Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine

Publications (2)

Publication Number Publication Date
EP0859636A1 EP0859636A1 (fr) 1998-08-26
EP0859636A4 true EP0859636A4 (fr) 2002-05-02

Family

ID=25645043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96934189A Withdrawn EP0859636A4 (fr) 1995-10-23 1996-10-22 Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine

Country Status (8)

Country Link
EP (1) EP0859636A4 (fr)
JP (1) JP2000507915A (fr)
KR (1) KR19990066967A (fr)
CN (1) CN1209068A (fr)
CA (1) CA2235685A1 (fr)
MY (1) MY134778A (fr)
NZ (1) NZ320006A (fr)
WO (1) WO1997015330A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268476A1 (fr) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Utilisation de hyaluronan dans la therapie genique
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2266622C (fr) 1996-09-27 2006-08-15 Hyal Pharmaceutical Corporation Systeme hyaluronique d'administration de medicaments
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
CN101011584A (zh) * 1999-12-28 2007-08-08 诺瓦提斯公司 获得持续的转基因表达的方法
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
DK1407787T3 (da) 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
CN1309392C (zh) 2002-02-15 2007-04-11 研究发展基金会 透明质酸介导的腺病毒转导
WO2004105784A1 (fr) * 2003-05-29 2004-12-09 The University Of Manchester Agonistes des slrp de classe iii servant a reduire la formation de vaisseaux sanguins
KR101145452B1 (ko) * 2004-10-05 2012-05-16 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 망막증을 선별검사하는 방법 및 장치
CN101184776B (zh) 2005-03-24 2013-04-24 斯路姆基因公司 新型抗胎盘生长因子抗体
WO2007003609A1 (fr) 2005-06-30 2007-01-11 Vib Vzw Traitement de la cirrhose hepatique et de ses complications
CN1742623A (zh) * 2005-07-13 2006-03-08 凌沛学 透明质酸磷脂复合物及其制备方法
KR101798664B1 (ko) 2008-10-02 2017-11-16 브이아이비 브이지더블유 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
KR101420751B1 (ko) * 2011-12-12 2014-07-17 서강대학교산학협력단 망막 질환 치료제 후보물질의 스크리닝 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636339B1 (fr) * 1988-09-09 1992-07-17 Auge Pier Gel aqueux a base d'acide hyaluronique et d'acide desoxyribonucleique utilisable en cosmetique, et procede de preparation
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
AU1469292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating expression of growth factor genes and growth factor receptor genes
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
EP0769552A4 (fr) * 1994-06-27 1997-06-18 Toagosei Co Ltd Compose d'acide nucleique antisens

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CANCERLIT [online] NATIONAL CANCER INSTITUTE, BETHESDA, MD, US; MITCHELL SD ET AL: "Antisense RNA to the cell adhesion gene CD44 in melanoma cells (Meeting abstract).", XP002177966, retrieved from DIALOG accession no. 01061823 Database accession no. 94699907 *
ELLIS LM ET AL: "Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation.", SURGERY, NOV 1996, VOL. 120, NO. 5, PAGE(S) 871-878, XP001027824, ISSN: 0039-6060 *
J PATHOL; 170, 1993, (SUPPL), ISSN: 0022-3417 *
MUMPER R J ET AL: "NOVEL POLYMERIC CONDENSING CARRIERS FOR GENE DELIVERY", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, XX, XX, vol. 22, 30 July 1995 (1995-07-30), pages 178, XP002048876, ISSN: 1022-0178 *
ROBINSON GREGORY S ET AL: "Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 10, 1996, pages 4851 - 4856, XP002137716, ISSN: 0027-8424 *
See also references of WO9715330A1 *
SMITH L E H ET AL: "INHIBITION OF PROLIFERATIVE RETINOPATHY USING ANTISENSE PHOSPHOROTHIOATE OLIGONUCLEOTIDES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF/VPF)", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 36, no. 4, 15 March 1995 (1995-03-15), pages S871, abstract no. 3992, XP002008713, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO1997015330A1 (fr) 1997-05-01
EP0859636A1 (fr) 1998-08-26
CN1209068A (zh) 1999-02-24
CA2235685A1 (fr) 1997-05-01
MY134778A (en) 2007-12-31
NZ320006A (en) 2001-12-21
JP2000507915A (ja) 2000-06-27
KR19990066967A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
EP0859636A4 (fr) Acide hyaluronique utilise comme porteur d'adn pour une therapie genique et adn anti-sens du facteur de croissance de l'endothelium vasculaire pour le traitement d'une vascularisation anormale de la retine
WO2001048190A3 (fr) Utilisations therapeutiques d'oligonucleotides a lna modifie
RU2004108061A (ru) Способ лечения онкологических заболеваний
EP1190099A4 (fr) Modulation antisens de l'expression de pi3k p85
DE69720481D1 (de) Verfahren zur verwendung von oligonukleotiden mit modifizierten cpg dinukleosiden
EP0714449A4 (fr) Modulation oligonucleotidique de la proteine kinase c
AU2001290706A1 (en) Antisense modulation of clusterin expression
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
WO1999015643A3 (fr) COMPOSITIONS OLIGONUCLEOTIDIQUES ANTISENSE CIBLEES SUR L'ARNm DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET METHODES D'UTILISATION
WO2002083184A3 (fr) Therapie genique avec des oligonucleotides chimeriques administres selon une methode comportant une etape d'iontophorese
AU2672099A (en) Compositions and methods for wound healing
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
EP1250347A4 (fr) Modulation antisens de l'expression de akt-3
EP1185696A4 (fr) Modulation oligonucleotidique antisens de l'expression de la proteine kinase c-delta humaine
WO2001070993A3 (fr) Polynucleotides agissant sur des genes de desaturase-delta-6 et techniques d'identification de composes permettant de moduler la desaturase-delta-6
WO1997010334A3 (fr) Therapie ribozymiale pour le traitement et/ou la prevention de la restenose
NO991292L (no) Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser
EP1165145A4 (fr) Regulation antisens d'expression de mdmx
WO2003087411A8 (fr) Procede d'inhibition de croissance cellulaire au moyen d'oligonucleotides
Grimpe Deoxyribozymes: new therapeutics to treat central nervous system disorders
WO2000062815A3 (fr) Nouvelle composition pharmaceutique utilisable en therapie genique
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
EP1173458A4 (fr) Modulation antisens de l'expression de sra

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/11 A, 7A 61K 48/00 B, 7A 61K 47/48 B, 7C 07K 14/52 B, 7A 61K 47/36 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020313

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20061010